CA2462682A1 - The use of gammaglobulin for the treatment of immune-mediated diseases - Google Patents

The use of gammaglobulin for the treatment of immune-mediated diseases Download PDF

Info

Publication number
CA2462682A1
CA2462682A1 CA002462682A CA2462682A CA2462682A1 CA 2462682 A1 CA2462682 A1 CA 2462682A1 CA 002462682 A CA002462682 A CA 002462682A CA 2462682 A CA2462682 A CA 2462682A CA 2462682 A1 CA2462682 A1 CA 2462682A1
Authority
CA
Canada
Prior art keywords
immunoglobulin
subject
immune
disease
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002462682A
Other languages
English (en)
French (fr)
Inventor
Leon E. Barstow
Richard Weisbart
James A. Ostrem
F. Javier Enriquez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protein Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2462682A1 publication Critical patent/CA2462682A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002462682A 2001-10-04 2002-10-04 The use of gammaglobulin for the treatment of immune-mediated diseases Abandoned CA2462682A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32704301P 2001-10-04 2001-10-04
US60/327,043 2001-10-04
US38096002P 2002-05-16 2002-05-16
US60/380,960 2002-05-16
PCT/US2002/033322 WO2003028668A2 (en) 2001-10-04 2002-10-04 Gammaglobulin treatment of immune disorders

Publications (1)

Publication Number Publication Date
CA2462682A1 true CA2462682A1 (en) 2003-04-10

Family

ID=26985697

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002462682A Abandoned CA2462682A1 (en) 2001-10-04 2002-10-04 The use of gammaglobulin for the treatment of immune-mediated diseases

Country Status (6)

Country Link
US (1) US20030099635A1 (https=)
EP (1) EP1463527A4 (https=)
JP (1) JP2005508338A (https=)
CA (1) CA2462682A1 (https=)
MX (1) MXPA04003156A (https=)
WO (1) WO2003028668A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082217A2 (en) * 2002-03-29 2003-10-09 Repligen Corporation Ctla4 compositions in the treatment of autism
US20090280114A1 (en) * 2002-04-12 2009-11-12 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2006014911A2 (en) * 2004-07-26 2006-02-09 Kossor David C Treatment of inflammatory, autoimmune, or other disorders, using agents that reduce the sequestering of zinc by calprotectin
JP2007284351A (ja) * 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
WO2006073682A2 (en) * 2004-12-09 2006-07-13 Meso Scale Technologies, Llc Diagnostic test
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
AU2008286361B2 (en) 2007-08-13 2013-09-26 Takeda Pharmaceutical Company Limited IVIG modulation of chemokines for treatment of multiple sclerosis, Alzheimer's disease, and Parkinson's disease
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
EP2427497B1 (fr) * 2009-05-07 2016-12-07 Stallergenes Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale
MX2011012576A (es) 2009-05-27 2012-05-08 Baxter Int Metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo.
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
CN103025347A (zh) * 2010-04-23 2013-04-03 普若拜特有限公司 药用组合物
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
JP6379113B2 (ja) 2013-02-26 2018-08-22 バクスアルタ インコーポレイテッド 免疫グロブリンｇの鼻腔内投与による中枢神経系障害の治療
LT2994160T (lt) 2013-05-06 2019-08-26 Baxalta Incorporated Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g
US10478493B2 (en) 2015-08-31 2019-11-19 Stolle Milk Biologics, Inc. Method of treating protozoal gastrointestinal disorders in immunocompromised patients
ES2690178A1 (es) * 2017-05-18 2018-11-19 Apc Europe Slu Plasma de animal o fracciones del mismo para su utilización en el tratamiento de trastornos de deterioro cognitivo en seres humanos y animales de compañia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33565E (en) * 1978-02-06 1991-04-02 Stolle Research And Development Corporation Prevention and treatment of rheumatioid arthritis
US4477432A (en) * 1981-05-01 1984-10-16 Cutter Laboratories, Inc. Oral immune globulin
US4897265A (en) * 1983-10-27 1990-01-30 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
US5242691A (en) * 1982-06-03 1993-09-07 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
US5106618A (en) * 1987-07-02 1992-04-21 Stolle Research And Development Corporation Method of treating protozoal gastrointestinal disorders by administering hyperimmune milk product
WO1993000077A1 (en) * 1991-06-21 1993-01-07 University Of Cincinnati Orally administrable therapeutic proteins and method of making
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5455160A (en) * 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
US6090380A (en) * 1994-01-12 2000-07-18 Research Corporation Technologies, Inc. Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin
JPH10212246A (ja) * 1997-01-30 1998-08-11 Nippon Zoki Pharmaceut Co Ltd 経口投与用製剤
CA2290556A1 (en) * 1997-05-19 1998-11-26 Repligen Corporation Method for assisting in differential diagnosis and treatment of autistic syndromes
US20020114802A1 (en) * 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
EP1076665A1 (en) * 1998-05-07 2001-02-21 Research Corporation Technologies, Inc Oral administration of immunoglobulins for treating autoimmune hearing loss
CA2340884A1 (en) * 1998-08-25 2000-03-02 Human Genome Sciences, Inc. 49 human secreted proteins
CA2370268A1 (en) * 1999-04-19 2000-10-26 Richard Weisbart Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid
US6187309B1 (en) * 1999-09-14 2001-02-13 Milkaus Laboratory, Inc. Method for treatment of symptoms of central nervous system disorders

Also Published As

Publication number Publication date
MXPA04003156A (es) 2005-01-25
EP1463527A4 (en) 2005-05-11
EP1463527A2 (en) 2004-10-06
US20030099635A1 (en) 2003-05-29
WO2003028668A2 (en) 2003-04-10
JP2005508338A (ja) 2005-03-31
WO2003028668A3 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
US20030099635A1 (en) Use of oral gammaglobulin for the treatment of immune-mediated diseases
US10912955B2 (en) Treatment of celiac disease, C. difficile infection, food intolerance and food allergy with secretory IgA/IgM
US6187309B1 (en) Method for treatment of symptoms of central nervous system disorders
US20030099633A1 (en) Methods and compositions for treatment of immune dysfunction disorders
JP5781514B2 (ja) Ｈｓｐ６５由来のペプチド６に特異的なヒト化抗体、その方法及び使用
US6713058B2 (en) Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
US20120045517A1 (en) TREATMENT OF CELIAC DISEASE WITH IgA
US8119104B2 (en) Treatment of celiac disease with IgA
US20190338021A1 (en) Therapies for treating inflammatory disorders
US6200565B1 (en) Oral administration of immunoglobulins for treating autoimmune hearing loss
AU2002348464A1 (en) Gammaglobulin treatment of immune disorders
US20020098182A1 (en) Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
RU2342951C1 (ru) Препарат, содержащий иммуноглобулин противооспенный из сыворотки крови лошадей, раствор для внутримышечного введения
WO2006036213A2 (en) The use of gammaglobulin for the treatment of periodontal disease
US20250326821A1 (en) PROCESS FOR PREPARATION OF SECRETORY IgA AND SECRETORY IgM AND USE THEREOF FOR TREATING NECROTIZING ENTEROCOLITIS
US20200109185A1 (en) Treatment of intestinal dysbiosis with immunoglobin
US12612467B2 (en) Treatment of necrotizing enterocolitis with semisynthetic polyclonal human secretory immunoglobin A
Class et al. Patent application title: TREATMENT OF INTESTINAL DYSBIOSIS WITH IMMUNOGLOBIN
CA2370268A1 (en) Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid
JP2026507912A (ja) 半合成ポリクローナルヒト分泌型免疫グロブリンａによる腸管腔免疫グロブリン欠乏の治療
CA2423805A1 (en) Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin g

Legal Events

Date Code Title Description
FZDE Discontinued